Effectiveness and Safety of Baricitinib in Severe Alopecia Areata: 48-Week Results

September 2025 in “ Journal of the European Academy of Dermatology and Venereology ”

Bianca Maria Piraccini, Stephano Cedirian, Francesca Pampaloni, Luca Rapparini, Federico Quadrelli, Francesca Bruni, Lorenzo Ala, Maria Cristina Acri, Alfredo Rossi, Giovanni Pellacani, Francesco Lacarrubba, Federica Dall’Oglio, Giuseppe Micali, Luciano Foggia, Mariateresa Cantelli, Paola Nappa, Laura Diluvio, Luigi Bianchi, Naldi Luigi, Anna Bolzon, Ketty Peris, Giacomo Caldarola, Giampiero Girolomoni, Federico Marangoni, Francesco Bellinato, Paolo Gisondi, G Silvi, Francesca Prignano, Nicola Pimpinelli, Carlo Tomasini, Stefania Barruscotti, Oriana Simonetti, Edoardo De Simoni, Francesca Ambrogio, Caterina Foti, Valeria Boccaletti, Alessandro Fraghì, Angelo Valerio Marzano, Maria Alessandra Mattioli, Silvia Mariel Ferrucci, Andrea Sechi, Luca Valtellini, Mauro Barbareschi, Giuseppe Gallo, Simone Ribero, Pietro Quaglino, Isotta Giunipero di Corteranzo, Riccardo Balestri, Calogero Pagliarello, Raffaele Dante Caposiena, Iris Zalaudek, Emanuele Vagnozzi, Maria Concetta Fargnoli, Chiara Caponio, Pietro Rubegni, Élisa Cinotti, Emanuele Trovato, Marco Romanelli, Valentina Dini, Flavia Manzo Margiotta, Claudio Feliciani, Maria Beatrice De Felici Del Giudice, Laura Atzori, Silvia Sanna, Serena Lembo, Annunziata Raimondo, Michela Magnano, Giuseppe Argenziano, Graziella Babino, Elisabetta Fulgione, Franco Rongioletti, Nazario Pesce, Stefania Guida, Alba Guglielmo, Natale Schettini, Michela Starace

baricitinib alopecia areata SALT score trichoscopic findings

TLDR Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.

The study assessed the effectiveness and safety of baricitinib, a JAK inhibitor, in treating severe alopecia areata over 48 weeks, involving 253 adult patients across 27 Italian university hospitals. Results showed that 63.2% of participants achieved a SALT score of ≤20 by week 48, indicating significant hair regrowth. The mean SALT score decreased from 93.7 to 26.5, and trichoscopic findings confirmed improvements in hair regrowth and reductions in hair loss indicators. Quality of life measures, such as Skindex-16 and HADS, improved significantly. Adverse events were reported in 9.4% of patients, supporting a favorable safety profile for baricitinib as a treatment for severe alopecia areata.

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

13 / 13 results

research Real-Life Effectiveness and Safety of Baricitinib in Patients with Severe Alopecia Areata: A 24-Week Italian Study

September 2024 in “Journal of the European Academy of Dermatology and Venereology”

Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.

Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib

research Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib

June 2024 in “Dermatology and Therapy”

Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.

research European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata

4 citations , January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.

Physician and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries

research Physician and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries

2 citations , October 2023 in “Dermatology and therapy”

Alopecia areata severely impacts quality of life, causing anxiety, depression, and work impairment.

research Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data

September 2023 in “Dermatology and Therapy”

Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.

Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials

research Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials

September 2023 in “British Journal of Dermatology”

Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.

Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials

research Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials

3 citations , June 2023 in “Journal of dermatological treatment”

Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.

research Baricitinib for the Treatment of Alopecia Areata

6 citations , May 2023 in “Drugs”

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials

20 citations , March 2023 in “American Journal of Clinical Dermatology”

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , March 2022 in “The New England Journal of Medicine”

Baricitinib was effective in treating alopecia areata in two major trials.

research Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management

290 citations , August 2021 in “Clinical Reviews in Allergy & Immunology”

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

research Common Causes of Hair Loss: Clinical Manifestations, Trichoscopy, and Therapy

47 citations , December 2020 in “Journal of the European Academy of Dermatology and Venereology”

The document concludes that understanding and treating hair loss requires recognizing its various types and using appropriate diagnostic tools and treatments.

research Italian Guidelines in Diagnosis and Treatment of Alopecia Areata

37 citations , December 2019 in “Giornale italiano di dermatologia e venereologia”

The Italian guidelines offer advice for diagnosing and treating alopecia areata based on expert opinion and limited clinical trial evidence.

Related Community Posts Join

6 / 14 results

Compressed part of research of theory of androgenic/anabolitic balance. AGA h-responders analytic. Theory of physio-metabolitic method of anti AGA treatment

community Compressed part of research of theory of androgenic/anabolitic balance. AGA h-responders analytic. Theory of physio-metabolitic method of anti AGA treatment

in Research 865 upvotes 1 year ago

The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.

community What are the odds baricitinib will get a topical otc version for androgenic alopecia?

in Research/Science 2 years ago

Baricitinib, approved for alopecia areata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.

community Lilly to seek first approval of an autoimmune drug for hair loss

in Research/Science 18 upvotes 4 years ago

Eli Lilly's drug baricitinib showed effectiveness in treating alopecia areata, with higher doses resulting in significant hair regrowth compared to placebo. The treatment is not for male pattern baldness.

community Anyone else taking Litfulo (ritlecitinib) to treat their alopecia?

in Treatment 7 upvotes 2 years ago

A user diagnosed with Alopecia Areata started using Litfulo (ritlecitinib), kenalog shots, and mometasone furoate 0.1%. They shaved their head and are seeking others' experiences with Litfulo.

community I am a dermatologist with a clinical interest in alopecia. AMA

in Will treatment work for me? 3 years ago

In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.

community Olumiant active ingredient Baricitinib

in Research/Science 1 upvotes 2 years ago

The conversation is about someone inquiring if anyone has tried Olumiant or its active ingredient, Baricitinib, for hair loss, mentioning the cost and that they have ordered Baricitinib.

Related Research

1 / 1 results

research Serum Zinc Concentration in Patients With Alopecia Areata

October 2023 in “Acta dermato-venereologica (Print)”

People with severe hair loss have lower zinc levels in their blood.